ENAapplication/xmlftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR163/038/SRR16387638/SRR16387638_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR163/044/SRR16387644/SRR16387644_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR163/042/SRR16387642/SRR16387642_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR163/034/SRR16387634/SRR16387634_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR163/036/SRR16387636/SRR16387636_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR163/043/SRR16387643/SRR16387643_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR163/044/SRR16387644/SRR16387644_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR163/037/SRR16387637/SRR16387637_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR163/040/SRR16387640/SRR16387640_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR163/041/SRR16387641/SRR16387641_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR163/034/SRR16387634/SRR16387634_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR163/037/SRR16387637/SRR16387637_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR163/041/SRR16387641/SRR16387641_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR163/035/SRR16387635/SRR16387635_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR163/038/SRR16387638/SRR16387638_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR163/035/SRR16387635/SRR16387635_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR163/039/SRR16387639/SRR16387639_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR163/033/SRR16387633/SRR16387633_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR163/039/SRR16387639/SRR16387639_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR163/036/SRR16387636/SRR16387636_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR163/033/SRR16387633/SRR16387633_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR163/043/SRR16387643/SRR16387643_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR163/042/SRR16387642/SRR16387642_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR163/040/SRR16387640/SRR16387640_2.fastq.gzprimaryOK200GenomicsShanghai Institute for Biomedical and Pharmaceutical Technologieshttps://www.ebi.ac.uk/ena/browser/view/PRJNA772104E-jiao, a traditional Chinese medicine with more than 2000 years of application, has been used clinically to treat ovarian-related diseases, but animal experimental studies to comprehensively investigate its effects on the ovaries and the possible mechanisms involved are lacking. In this study, two intraperitoneal injections of 80 mg/kg cyclophosphamide induced ovarian damage in rats. After oral administration of 4.5 g/kg E-jiao for 4 weeks, the therapeutic effect of E-jiao on rat ovary was investigated. The possible mechanism was systematically revealed by RNA sequencing.ENATherapy, RNA, Rat, RNA Sequence Determination, norvegicus, determination, Laboratory, RNA Sequence Determinations, Sequence Determination, RNA Sequence, Alpha-dystrobrevin-associated MAGE Protein, Norway Rat, Rattus, Norway Rats, Determinations, MAGE-E1 antigen, rat, Rattus sp. strain Wistar, Mus norvegicus, Rattus norwegicus, Rats, Laboratory Rats, chemical analysis, DAMAGE, Hepatocellular carcinoma-associated protein 1, Norway rat, Analysis, Rattus rattiscus, brown rat, treatment, Rattus norvegicus, Analyses, Determination, RGD1560259, AI847422, Sequence Determinations, rats, Treatments, Sequencing, Laboratory Rat., RNA Sequence Analyses, Therapeutic, HCA1, RNA Sequence Analysis, disease management, Therapies, RNA Sequencing, Treatment, assay, Norway, mMage-e1, Sequence Analyses, Rattus norvegicus8, Gunn ratsfalseRNA sequencing analysis of E-jiao in the treatment of ovarian damage in rats2023-05-192021-10-20PRJNA772104